InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,035.09
(
-1.34%
)
Post# of 6070
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

operating_line

Send PM Follow Ignore
Followers 8
Posts 921
Boards Moderated 0
Alias Born 10/07/2015

operating_line

Re: None

Saturday, 11/06/2021 5:42:23 AM

Saturday, November 06, 2021 5:42:23 AM

Post# of 6070
Latest from CASI Pharmaceuticals

"The Company also has greater China rights to ZEVALIN® (Ibritumomab Tiuxetan) and MARQIBO® (vincristine sulfate LIPOSOME injection), each of which is approved in the United States by the FDA for specified indications. Due to the evolving standard of care environment, the rare and niche indication for these products, and the Company’s commitment to prioritize resources, the Company is currently evaluating its options for these products."

https://www.streetinsider.com/SEC+Filings/Form+424B5+CASI+Pharmaceuticals%2C/19130686.html
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up